Human Papillomavirus infection and cervical carcinoma

Clinical Obstetrics and Gynecology

Volumn 43, Issue 2, 2000, Pages 363-380

  Kaufman, Raymond H ^a   Adam, Ervin ^a   Vonka, Vladimir ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GRADING; CANCER RISK; CANCER SCREENING; CONDYLOMA; CONFERENCE PAPER; FEMALE; HUMAN; PAPANICOLAOU TEST; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CARCINOMA; UTERINE CERVIX TUMOR;

FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0033938098     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200006000-00016     Document Type: Conference Paper

References (122)

1. Strauss MJ, Bunting H, Melnick JL. Virus-like particles and inclusion bodies in skin papillomas. J Invest Dermatol. 1950; 15:433-444.
2. Shope RE, Hurst EW. Infectious papillomatosis of rabbits, with a note on the histopathology. J Exp Med. 1933;58:607-624.
3. Rous PJB. The progression to carcinoma of virus-induced rabbit papillomas (Shope). J Exp Med. 1935;62:523-548.
4. Orth G, Jablonska S, Jarzabek-Chorzelska M, et al. Characteristics of the lesions and risk of malignant conversion associated with the type of human papillomavirus involved in epidermodysplasia verruciformis. Cancer Res. 1979;39:1074-1082.
5. Miyamoto T, Sasaoka R, Hagari Y, Mikara M. Association of cutaneous verrucous carcinoma with human papillomavirus type 16. Br J Dermatol. 1999;140:168.
6. Chiang CM, Ustav M, Stenlund A, Ho TF, Broker TR, Chow LT. Viral E1 and E2 proteins support replication of homologous and heterologous papillomavirus origins. Proc Natl Acad Sci USA. 1992;89: 5799-5803.
7. Liu JS, Kuo SR, Broker TR, Chow LT. The functions of human papillomavirus 11 E1, E2, and E2C proteins in cell-free DNA replication. J Biol Chem. 1995;270: 27283-27291.
8. McBride A, Romanczuk H, Howley PM. The papillomavirus E2 regulatory proteins. J Biol Chem. 1991;266;18411-18418.
9. Doorbar J, Ely S, Sterling J, McLean S, Crawford L. Specific interaction between HPV16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature. 1991;352:824-827.
10. Galloway DA, McDougall JK. The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Sem Cancer Biol. 1996;7:309-315.
11. Matsukura T, Koi S, Sugase M. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology 1989; 172:63-62.
12. Zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991;184:9-13.
13. Zur Hausen H. Are human papillomavirus infections not necessary or sufficient causal factors for invasive cancer of the cervix. Int J Cancer. 1995;63:315-316.
14. Ponten J, Adami H, Friberg L, et al. HPV and cervical cancer. Int J Cancer. 1995; 63:317.
15. Zur Hausen H. Papillomavirus infections: A major cause of human cancers. Biochim Biophys Acta. 1996;1288:F55-F78.
16. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 1993; 54:594-601.
17. Munoz N, Bosch FX, de Sanjose S, et al. The causal link between human papillomavirus and invasive cervical cancer: A population-based case-control study in Colombia and Spain. Int J Cancer. 1992; 52:743-749.
18. Schiffman MH. New epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst. 1995;87: 1345-1347.
19. Dillner J. Antibody responses to defined HPV epitopes in cervical neoplasia. Papillomavirus Rep. 1994;5:35-41.
20. Galloway DA. HPV serology. Another update. In: Lacey C, ed. Papillomavirus Reviews: Current Research on Papillomaviruses. London: Leeds University Press, 1996:113-119.
21. De Sanjose S, Hamšíková E, Muňoz N, et al. Serological response to HPV16 in CIN III and cervical cancer patients. Case-control studies in Spain and Colombia. Int J Cancer. 1996;66:70-74.
22. De Gruijl TD, Bontkes HJ, Walboomers JMM, et al. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst. 1997;89:630-638.
23. Viladiu P, Bosch FX, Castellsague X, et al. Human papillomavirus DNA and antibodies to human papillomavirus 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer. J Clin Oncol. 1997;15:610-619.
24. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis. 1996;174:927-936.
25. Lehtinen M, Dillner J, Knekt P, et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: Nested case-control study. BMJ. 1996;312:537-539.
26. Dillner J, Lehtinen M, Bjorge T, et al. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst. 1997;89:1293-1299.
27. Kjellberg L, Wang ZH, Wiklund F, et al. Sexual behavior and papillomavirus exposure in cervical intraepithelial neoplasia: A population-based case-control study. J Gen Virol. 1999;80:391-398.
28. Vonka V, Hamšíková E, Kaňka J, Ludvíková V, Sapp M, Šmahel M. Prospective study on cervical neoplasia. IV. Presence of HPV antibodies. Int J Cancer. 1999;80:365-368.
29. Chaouki N, Bosch FX, Muňoz N, et al. The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer. 1998;75:546-554.
30. Karlsson R, Jonsson M, Edlund K, et al. Lifetime number for partners as the only independent risk factor of human papillomavirus infection: A population-based study. Sex Trans Dis. 1995;22:119-127.
31. Svare EI, Kjaer SK, Worm A, et al. Risk factors for HPV infection in women from sexually transmitted disease clinics: Comparison between two areas with different cervical cancer incidence. Int J Cancer. 1998;75:1-8.
32. Burk RD, Kelly P, Feldman J, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Trans Dis. 1996;23:333-341.
33. Muňoz N, Kato I, Bosch X, et al. Risk factors for HPV DNA detection in middleaged women. Sex Trans Dis. 1996;23:504-510.
34. Ley C, Bauer HM, Reingold A, et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst. 1991;84:997-1003.
35. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervico-vaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-427.
36. Muňoz N, Castellsague X, Bosch FX, et al. Difficulty in elucidating the male role in cervical cancer in Colombia, a high-risk area for the disease. J Natl Cancer Inst 1996;88:1068-1075.
37. O'Hanlan KA, Crum CP. Human papillomavirus-associated cervical intraepithelial neoplasia following lesbian sex. Obstet Gynecol. 1996;88:702-703.
38. Bacheco BP, Di Paola G, Ribas JMM, Vighi S, Rueda NG. Vulvar infection caused by human papilloma virus in children and adolescents without sexual contact. Adolesc Pediatr Gynecol. 1991;4:136-142.
39. Sedlaček TV, Lindheim S, Eder C, et al. Mechanism for human papillomavirus transmission at birth. Am J Obstet Gynecol. 1989;161:55-59.
40. Tenti P, Zappatore R, Migliora P, Spinillo A, Belloni C, Carnevali L. Perinatal transmission of human papillomavirus from gravidas with latent infections. Obstet Gynecol. 1999;93:475-479.
41. Puranen MH, Yiskoski MH, Saarikoski SV, Syrjanen KJ, Syrjanen SM. Exposure of an infant to cervical human papillomavirus infection of the mother is common. Am J Obstet Gynecol. 1997;176:1039-1045.
42. Kaye JN, Starkey WG, Kell B, et al. Human papillomavirus type 16 in infants: Use of DNA sequence analyses to determine the source of infection. Gen Virol. 1996;77:1139-1143.
43. Jenison SA, Yu X, Valentine JM, et al. Evidence of prevalent genital-type human Papillomavirus infections in adults and children. J Infect Dis. 1990;162:60-69.
44. Melkert PWJ, Hopman E, Van Den Brule AJC, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer. 1993; 53:919-923.
45. Evander M, Edlund K, Gustafsson A, et al. Human papillomavirus infection is transient in young women: A population based cohort study. J Infect Dis. 1995; 171:1026-1030.
46. Wheeler CM, Greer CE, Becker TM, Hunt WC, Anderson SM, Manos MM. Shortterm fluctuations in the detection of cervical human papillomavirus DNA. Obstet Gynecol. 1996;88:261-268.
47. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-240.
48. Remmink AJ, Walboomers JMM, Helmerhorst TJM, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. Int J Cancer. 1995;61: 306-311.
49. Londersborouth P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. Human papillomavirus genotypes as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int. J Cancer. 1996;69:364-368.
50. Vandenvelde C, Van Beers D. Risk factors inducing the persistence of high-risk genital papillomaviruses in the normal cervix. J Med Virol. 1992;38:226-232.
51. Fife KH, Katz BP, Brizendine EJ, Brown DR. Cervical human papillomavirus deoxyribonucleic acid persists throughout pregnancy and decreases in the postpartum period. Am J Obstet Gynecol. 1999; 180:1110-1114.
52. Bosch FX, Manos MM, Muňoz N, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst. 1995;87:796-802.
53. Ho L, Chan S, Chow V, et al. Sequence variants of human papillomavirus type 16 in clinical samples permit verification and extension of epidemiological studies and construction of a phylogenetic tree. J Clin Microbiol. 1991;29:1765-1772..
54. Hecht JL, Kadish AS, Jiang G, Burk RD. Genetic characterization of the human papillomavirus (HPV) 18 E2 gene in clinical specimens suggests the presence of a subtype with decreased oncogenic potential. Int J Cancer. 1995;60:369-376.
55. Xi LF, Koutsky LA, Galloway DA, et al. Genomic variation of human papillomavirus type 16 and risk for high-grade cervical intraepithelial neoplasia. J Natl Cancer Inst. 1997;89:796-802.
56. Yamada T, Manos, MM, Peto J, et al. Human papillomavirus type 16 sequence variation in cervical cancers: A worldwide perspective. Virology. 1997;71:2463-2472.
57. Zehbe I, Voglino G, Delius H, Wilander E, Tommasino M. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphism. Lancet. 1998;352:1441-1442.
58. Kaufman RH, Adam E. Is human papillomavirus testing of value in clinical practice? Am J Obstet Gynecol. 1999;180:1049-1053.
59. Pao CC, Kao SM, Tang GC, Lee K, Si J, Ruan S. Prevalence of human papillomavirus DNA sequences in an area with very high incidence of cervical carcinoma. Br J Cancer. 1994;70:694-696.
60. Zur Hausen H. Human genital cancer: Synergism between two virus infections or synergism between a virus infection and initiating events. Lancet. 1982;2:1370-1372.
61. Melnick JL, Rawls WE, Adam E. Viral infections of humans. Epidemiology and control. In: Evans A, ed. Cervical cancer. New York: Planum Medical Book Company, 1989:687-711.
62. Vonka V, Kaňka J, Hirsch I, et al. Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type-2 antibody presence in sera taken at enrollment. Int J Cancer. 1984;33:61-66.
63. Baldauf JJ, Dreyfus M, Monlun E, Ritter J, Obert G. Increased prevalence of herpes viruses in high-grade CIN and carcinoma of the cervix: The potential for synergistic effect. J Eur Acad Dermatol Venereol. 1995;4:104-109.
64. Hildesheim A, Mann V, Brinton LA, et al. Herpes simplex virus type 2: A possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer. Int J Cancer. 1991; 49:335-340.
65. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327:1272-1278.
66. Koffa M, Koumantakis E, Ergazaki M, Tsatsanis C, Spandidos, DA. Association of herpesvirus infection with the development of genital cancer. Int J Cancer. 1995; 63:58-62.
67. Kjaer SK, de Villiers EM, Caglayan H, et al. Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark): A second look. Br J Cancer. 1993;67:830-837.
68. De Sanjose S, Muňoz N, Bosch FX, et al. Sexually transmitted agents and cervical neoplasia in Colombia and Spain. Int J Cancer. 1994;56:358-363.
69. Winkelstein W Jr. Smoking and cervical cancer. Current status: A review. Am J Epidemiol. 1990;131:945-957.
70. Simons AM, van Herckenrode CM, Rodriguez JA, et al. Demonstration of smoking-related DNA damage in cervical epithelium and correlation with human papillomavirus type 16 using exfoliated cervical cells. Br J Cancer. 1995;71:246-249.
71. Burger MPM, Hollema H, Gouw ASH, Pieters WJLM, Quint WGV. Cigarette smoking and human papillomavirus in patients with reported cervical cytological abnormality. BMJ. 1993;306:749-752,
72. Brisson J, Morin C, Fortier M, et al. Risk factors for cervical intraepithelial neoplasia differences between low- and highgrade lesions. Am J Epidemiol. 1994;140: 700-710.
73. Adam E, Berková Z, Daxnerová Z, et al. Papillomavirus detection, histopathology, demographic and behavioral characteristics in identification of cervical disease. Am J Obstet Gynecol. 2000;182:257-264.
74. Yang X, Jin G, Nakao Y, Rahimtula M, Pater MM, Pater A. Malignant transformation of HPV 16-immortalized human endocervical cells by cigarette smoke condensate and characterization of multistage carcinogenesis. Int J Cancer. 1996;65:338-344.
75. Slattery ML, Robison LM, Schuman KL, et al. Cigarette smoking and exposure to passive smoke are risk factors for cervical cancer. JAMA. 1989;261:1593-1632
76. Jones CJ, Schiffman MH, Kurman R, Jacob P 3rd, Benowitz NL. Elevated nicotine levels in cervical lavages from passive smokers. Am J Publ Health. 1991;81: 378-379.
77. Brinton LA, Reeves WC, Brenes MM, et al. Parity as a risk factor for cervical cancer. Am J Epidemiol. 1989;130:486-496.
78. Thomas DB, Ray RM. Invasive squamous-cell cervical carcinoma and combined oral contraceptives: Results from a multinational study. Int J Cancer. 1993; 55:228-236.
79. Kjaer SK, Van Den Brule AJC, Bock JE, et al. Human papillomavirus: The most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer. 1996; 65:601-606.
80. Smits HL, Bollen LJM, Tjong-A-Hung SP, et al. Intermethod variation in detection of human papillomavirus DNA in cervical smears. J Clin Microbiol. 1995;33: 2631-2636.
81. Peyton CL, Schiffman M, Lorincz AT, et al. Comparison of PCR-and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol. 1998;36:3248-3254.
82. Skegg DCG. Cervical screening blues. Lancet. 1995;345:1451-1452.
83. Schiffman M, Solomon D, Liaw K, Sherman M. Why, how, and when the cytological diagnosis of ASCUS should be eliminated. J Lower Genital Tract Dis. 1998; 2:165-169.
84. Richart RM. Clinical Commentary. A modified terminology for cervical intraepithelial neoplasia. Obstet Gynecol. 1990;75:131-133.
85. Kiviat NB, Koutsky LA. Specific human papillomavirus types as the causal agents of most cervical intraepithelial neoplasia: Implications for current views and treatment. J Natl Cancer Inst. 1993;85:934-935.
86. Wright TC Jr, Kurman RJ. A critical review of the morphologic classification systems of preinvasive lesions of the cervix: The scientific basis for shifting the paradigm. Papillomavirus Report 1994;5: 175-182.
87. Burger MPM, Hollema H, Pieters WJLM, Schroder FP, Quint WGV. Epidemiological evidence of cervical intraepithelial neoplasia without the presence of human papillomavirus. Br J Cancer. 1996;73:831-836.
88. Kaufman RH, Adam E, Icenogle J, Reeves WC. Human papillomavirus testing as triage for atypical squamous cells of undermined significance and low-grade squamous intraepithelial lesions: Sensitivity, specificity, and cost effectiveness. Am J Obstet Gynecol. 1997;177:930-936.
89. Adam E, Kaufman RH, Berková Z, Icenogle J, Reeves WC. Is human papillomavirus testing an effective triage method for detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia? Am J Obstet Gynecol. 1998;178:1235-1244.
90. Vassilakos P, De Marval F, Muňoz M, Broquet G, Campana A. Human papillomavirus (HPV) DNA assay as an adjunct to liquid-based Pap test in diagnostic triage of women with abnormal Pap smear. Int J Gynecol Obstet. 1998;61:45-50.
91. Ferenczy A, Franco E, Arseneau J Wright TC, Richart RM. Diagnostic performance of hybrid capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study. Am J Obstet Gynecol. 1996;175:651-656.
92. Maňos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281:1605-1610.
93. Greenberg MD, Reid R, Schiffman M, et al. A prospective study of biopsy-confirmed cervical intraepithelial neoplasia grade 1: Colposcopic, cytological, and virological risk factors for progression. J Lower Genital Tract Dis. 1999;3:104-110.
94. Ferris DG, Wright TC Jr, Litaker MS, et al. Triage of women with ASCUS and LSIL on pap smear, HPV DNA testing, or colposcopy? J Fam Pract. 1998;46:125-134.
95. Ferris DG, Wright TC Jr, Litaker MS, et al. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL. J Fam Pract. 1998;46:136-141.
96. Clavel C, Masure M, Bory JP, et al. Hybrid capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: A preliminary study on 1,518 women. Br J Cancer. 1999;80:1306-1311.
97. Rozendaal L, Walboomers JMM, Van Der Linden JC, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer. 1996:68:766-769.
98. Schiller JT, Lowy DR. Papillomavirus-like particles and HPV vaccine development. Cancer Biol. 1996;7:373-382.
99. Bell JA, Sundberg JP, Ghim SJ, Newsome J, Jenson AB, Schlegel R. A formalininactivated vaccine protects against mucosal papillomavirus infection: A canine model. Pathobiology. 1994;62:194-198.
100. Hildesheim A. Human papillomavirus variants: Implication for natural history studies and vaccine development efforts. J Natl Cancer Inst. 1997;89:752-753.
101. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991;185: 251-257.
102. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA. 1992;89: 1280-1284.
103. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol. 1995;69:3959-3963.
104. Jansen KV, Rosolovsky M, Schulz LD, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine. 1995;13:1509-1514.
105. Donelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA. Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis. 1996;173: 314-320.
106. Selvakumar R, Borenstein LA, Lin Y-L, Ahmed R, Wettstein FO. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J Virol. 1995;69:602-605.
107. Jensen ER, Selvakumar R, Shen H, Ahmed R, Wettstein FO, Miller JF. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J Virol. 1997;71:8467-8474.
108. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papilloma virus types 16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 1996;347:1523-1527.
109. Muller M, Zhou J, Reed TD, et al. Chimeric papillomavirus-like particles. Virology. 1997;234:93-111.
110. Greenstone HL, Nieland JD, de Visser KE, et al. Chimeric papillomavirus-like particles elicit antitumor immunity against the E7 oncoprotein in a HPV16 tumor model. Proc Natl Acad Sci USA. 1998;95: 1800-1805.
111. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993;23:2242-2249.
112. Brandt RPM, Ressing ME, de Jong JH, et al. The HPV16 E7 peptide-based vaccine trial in endstage cervical carcinoma: Final report. Paper presented at 17th International Papillomavirus Conference, Charleston, South Carolina, USA, 1999, Abs. No. Imm/Vax-3.
113. Vonka V, Sobotková E, Hamšíková E, et al. Induction of antitumor immunity by suicide-gene-modified HPV16-transformed hamster cells. Int J Cancer. 1998; 77:470-475.
114. De Bruijn MLH, Schuurhuis DH, Vierboom MPM, et al. Immunization with papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res. 1998;58:724-731.
115. Santin AD, Hermonat PL, Ravaggi A, et al. Induction of human papillomavirus-specific CD4 (+) and CDS (+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16 and 18 positive cervical cancer. J Virol. 1999;73:5402-10.
116. Connor ME, Stern PL. Loss of MHC class-1 expression in cervical carcinoma. Int J Cancer. 1990;46:1029-1034.
117. Keating PJ, Cromme FV, Duggan-Keen M, et al. Frequency of downregulation of individual HLA-A and B alleles in cervical carcinomas in relationship to TAP-1 expression. Br J Cancer. 1995;72:405-411.
118. Crawford L. Prospects for cervical cancer vaccines. Cancer Surv. 1993;16:215-229
119. Reichman R, Balsley J, Carlin D, et al. Evaluation of the safety and immunogenicity of a recombinant HPV11 L1 virus-like particle vaccine in healthy adult volunteers. Paper presented at the 17th International Conference, Charleston, South Carolina, 1999, Abst. No. Imm/ Vax-2.
120. Zhang LF, Zhou J, Shao C, et al. A phase 1 trial of HPV6B virus-like particles as immunotherapy for genital warts. Paper presented at the 17th International Papillomavirus Conference, Charleston, South Carolina, 1999, Abst No. Imm/Vax 13.
121. Sznoll M, Zwierzina H. Immune monitoring of cancer vaccines. Ann Oncol. 996; 7:667-670.
122. McNeil C. HPV vaccine treatment trials proliferate, diversify. J Natl Cancer Inst. 1997;89:280-281.